These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 35233031)

  • 21. Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents.
    Abes S; Moulton HM; Clair P; Prevot P; Youngblood DS; Wu RP; Iversen PL; Lebleu B
    J Control Release; 2006 Dec; 116(3):304-13. PubMed ID: 17097177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted gene correction with 5' acridine-oligonucleotide conjugates.
    de Piédoue G; Andrieu-Soler C; Concordet JP; Maurisse R; Sun JS; Lopez B; Kuzniak I; Leboulch P; Feugeas JP
    Oligonucleotides; 2007; 17(2):258-63. PubMed ID: 17638529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel non-endocytic delivery of antisense oligonucleotides.
    Dokka S; Rojanasakul Y
    Adv Drug Deliv Rev; 2000 Oct; 44(1):35-49. PubMed ID: 11035196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines.
    Linnane E; Davey P; Zhang P; Puri S; Edbrooke M; Chiarparin E; Revenko AS; Macleod AR; Norman JC; Ross SJ
    Nucleic Acids Res; 2019 May; 47(9):4375-4392. PubMed ID: 30927008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delivery of RNA Therapeutics: The Great Endosomal Escape!
    Dowdy SF; Setten RL; Cui XS; Jadhav SG
    Nucleic Acid Ther; 2022 Oct; 32(5):361-368. PubMed ID: 35612432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking.
    Alam MR; Ming X; Dixit V; Fisher M; Chen X; Juliano RL
    Oligonucleotides; 2010 Apr; 20(2):103-9. PubMed ID: 20038250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of PepFect peptides for the delivery of splice-correcting oligonucleotides.
    Andaloussi SE; Lehto T; Lundin P; Langel U
    Methods Mol Biol; 2011; 683():361-73. PubMed ID: 21053143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delivery of phosphodiester oligonucleotides: can DOTAP/DOPE liposomes do the trick?
    Remaut K; Lucas B; Braeckmans K; Sanders NN; Demeester J; De Smedt SC
    Biochemistry; 2006 Feb; 45(6):1755-64. PubMed ID: 16460022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice.
    Roberts J; Palma E; Sazani P; Ørum H; Cho M; Kole R
    Mol Ther; 2006 Oct; 14(4):471-5. PubMed ID: 16854630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endosomal Escape of Antisense Oligonucleotides Internalized by Stabilin Receptors Is Regulated by Rab5C and EEA1 During Endosomal Maturation.
    Miller CM; Wan WB; Seth PP; Harris EN
    Nucleic Acid Ther; 2018 Apr; 28(2):86-96. PubMed ID: 29437530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytosolic delivery of antisense oligonucleotides by listeriolysin O-containing liposomes.
    Mathew E; Hardee GE; Bennett CF; Lee KD
    Gene Ther; 2003 Jul; 10(13):1105-15. PubMed ID: 12808441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular uptake and intracellular trafficking of oligonucleotides.
    Juliano RL; Carver K
    Adv Drug Deliv Rev; 2015 Jun; 87():35-45. PubMed ID: 25881722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis.
    Ming X
    Expert Opin Drug Deliv; 2011 Apr; 8(4):435-49. PubMed ID: 21381985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incorporation of Endosomolytic Peptides with Varying Disruption Mechanisms into EGFR-Targeted Protein Conjugates: The Effect on Intracellular Protein Delivery and EGFR Specificity in Breast Cancer Cells.
    Lieser RM; Li Q; Chen W; Sullivan MO
    Mol Pharm; 2022 Feb; 19(2):661-673. PubMed ID: 35040326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Extrahepatic Targeting of Oligonucleotides with Receptor-Binding Non-Immunoglobulin Scaffold Proteins.
    Winkler J
    Nucleic Acid Ther; 2018 Jun; 28(3):137-145. PubMed ID: 29733239
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PepFect15, a novel endosomolytic cell-penetrating peptide for oligonucleotide delivery via scavenger receptors.
    Lindberg S; Muñoz-Alarcón A; Helmfors H; Mosqueira D; Gyllborg D; Tudoran O; Langel U
    Int J Pharm; 2013 Jan; 441(1-2):242-7. PubMed ID: 23200958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel graft copolymers enhance in vitro delivery of antisense oligonucleotides in the presence of serum.
    Peddada LY; Harris NK; Devore DI; Roth CM
    J Control Release; 2009 Dec; 140(2):134-40. PubMed ID: 19699243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Delivery of Oligonucleotide Therapeutics: Chemical Modifications, Lipid Nanoparticles, and Extracellular Vesicles.
    Bost JP; Barriga H; Holme MN; Gallud A; Maugeri M; Gupta D; Lehto T; Valadi H; Esbjörner EK; Stevens MM; El-Andaloussi S
    ACS Nano; 2021 Sep; 15(9):13993-14021. PubMed ID: 34505766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Splice-Switching Antisense Oligonucleotides as a Targeted Intrinsic Engineering Tool for Generating Armored Redirected T Cells.
    Ceccarello E; Tabaglio T; Koh S; Oei V; Teo W; Jonathan OJ; Pavesi A; Chen Q; Bertoletti A; Wee KB; Guccione E
    Nucleic Acid Ther; 2021 Apr; 31(2):145-154. PubMed ID: 33567222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system.
    Hu Q; Bally MB; Madden TD
    Nucleic Acids Res; 2002 Aug; 30(16):3632-41. PubMed ID: 12177306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.